🇺🇸 FDA
Pipeline program

Surzebiclimab

BGB-900-102

Phase 2 small_molecule completed

Quick answer

Surzebiclimab for Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in is a Phase 2 program (small_molecule) at BeOne Medicines with 1 ClinicalTrials.gov record(s).

Program details

Company
BeOne Medicines
Indication
Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials